have been reported up to 90 days after total hip replacement (THR) or total knee replacement (TKR) surgery, respectively, and 45% to 80% of all symptomatic DVTs in patients undergoing THR or TKR occur after hospital discharge. 1 With modern thromboprophylaxis, fatal PE is much more infrequent than previously assumed, with rates after THR or TKR and hip fracture (HF) of <0.5% and <1%, respectively. 2 There are few data regarding the incidence of VTE in other types of orthopedic surgery.
Bemiparin (Hibor®, Zibor®, Ivor®, Badyket®) is a second-generation LMWH, 3 with the lowest mean molecular weight (3600 Da) and the highest ratio anti-Xa/anti-IIa (8:1) of all LMWH currently marketed. The available experience for bemiparin during comparative clinical trials in orthopedic surgery shows its superiority over unfractionated heparin for prevention of venographically documented DVT after THR, 4 and a trend toward a lower incidence of proximal DVT, PE, and documented symptomatic VTE when compared to enoxaparin in TKR, with a similar safety profile. 5 This observational study was designed to gain additional clinical experience with bemiparin in a large population of orthopedic patients in normal clinical practice. Orthopedic patients were the targets of choice because VTE risk remains high for several weeks after orthopedic surgery/injury, and they usually receive extended outpatient prophylaxis. This allowed physicians to evaluate bemiparin effectiveness and safety in a relative wide extent of exposure. In addition, the orthopedic population is heterogeneous, and this study could allow for collecting data from different orthopedic settings (not only THR or TKR) in which LMWHs are used as thromboprophylaxis and data are scarce, such as cast immobilization of the leg, knee arthroscopy, or spine surgery. Finally, it was also intended to analyze the influence of concomitant factors (bemiparin dose, concomitant medications, age, and obesity) on VTE and bleeding rates, and also to assess the incidence of potential rare or unexpected adverse reactions to bemiparin.
Materials and Methods
This study was designed as a prospective, uncontrolled, open-label, multicenter, observational "real life" audit on the use of a new LMWH, bemiparin, in orthopedic patients. The study was conducted according to the Spanish requirements for observational studies (Circular 4/2000 of the Spanish Medicines Agency) and European Guidelines (CPMP/ PhVWP/109/99/corr).
The study population included patients treated primarily on an outpatient basis (eg, cast immobilization of the leg), but also all patients who, according to the physicians' criteria, started to receive prophylaxis at the hospital but were planned to receive extended prophylaxis outside the hospital (eg, HF surgery with prolonged outpatient prophylaxis). There were no pre-established exclusion criteria in the protocol. However, patients with insufficient data on reason for prophylaxis or lack of outcome assessment were excluded for the analysis.
Patients received open-label prophylaxis with once-daily, subcutaneous administration of bemiparin 3500 IU or 2500 IU/d, depending on whether they had a high or moderate risk, respectively, according to physicians' criteria.
Two visits were performed: the first one at the time bemiparin prophylaxis was started (initial visit) and the second at the end of bemiparin prophylaxis (outcome assessment visit), according to usual clinical practice. The following data were recorded in the case report form during the initial visit: demographic characteristics (age, sex, weight, height), reason for prophylaxis (orthopedic procedures), VTE risk stratification, and data on bemiparin prophylaxis. Use of concomitant medications that could alter hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and/or antiplatelet drugs, was recorded in the case report forms. Nonpharmacological treatments, such as active or passive mobilization or elastic bandages, were used according to the usual practice at each center and were recorded in the case report form. In the outcome assessment visit, the following events were recorded: symptomatic VTE (DVT and/or PE) confirmed by objective testing (Doppler ultrasound or ascending contrast venography for DVT and high-probability lung scanning, pulmonary angiography for PE, or necropsy in fatal cases); major bleeding (any bleeding in critical organs [intracranial, spinal, retroperitoneal, or intraocular bleeding], fatal bleeding, bleeding requiring reoperation to control bleed, or any bleeding requiring treatment cessation); minor bleeding (if it did not meet the criteria for major bleeding); thrombocytopenia (platelet count < 150 000/mm 3 ); deaths; and injection site complications.
We analyzed major and minor bleeding rates depending on the bemiparin dose used (2500 IU vs 3500 IU) and also depending on the concomitant administration of NSAIDs. Finally, we analyzed the rates of documented symptomatic VTE and major bleeding in the elderly, defined as age ≥ 65 years, and obesity, defined as a body mass index (BMI; calculated as weight in kilograms divided by the square of height in meters) of 30 kg/m 2 or greater for men and 28.6 kg/m 2 or greater for women.
Statistical Analysis
Ninety-five percent confidence intervals were calculated for the rates of VTE, major and minor bleeding events, deaths, thrombocytopenia, and injection site complications. Dichotomous data comparing bemiparin dose (2500 IU vs 3500 IU), NSAID versus no NSAID taking, elderly versus younger patients, and obese versus nonobese were evaluated with a 2-sided Fisher exact test. These calculations were performed using SPSS software, version 7.5 (Chicago, Illinois).
Results

Study Population and Baseline Characteristics
From November 2000 to March 2003, 7959 orthopedic patients with moderate to high VTE risk and needing thromboprophylaxis were enrolled in 157 Spanish centers. Of these, 6456 patients were included in the analysis of VTE and adverse events. The remaining patients had insufficient data on reason for prophylaxis (943 patients) or had baseline visit with no outcome assessment (560 patients) and therefore were excluded for the analysis of clinical events.
The baseline characteristics of patients included in the study are shown in Table 1 . Overall, mean patient age was 54.7 years, and 56.1% were female. Patients undergoing HF surgery, THR, or TKR had a mean age of 75.3 years, 66.7 years, and 66.5 years, respectively. In addition, patients undergoing knee arthroscopy had a mean age of 41.6 years, and 64.2% were male. Once-daily subcutaneous bemiparin 3500 IU was used in 84.9% of patients (high risk of VTE), whereas bemiparin 2500 IU was administered in 15.1% of patients (moderate risk of VTE). Bemiparin 3500 IU was administered in 75% of patients undergoing knee arthroscopy. Reason for prophylaxis is shown in Table 1 . Most patients had cast immobilization of the leg (lower limb trauma not requiring surgery but needing immobilization). "Other lower limb surgery" includes surgery of the lower limb different from HF, THR, or TKR (ie, surgery for femur, knee, calf, or ankle/foot fractures).
Overall, bemiparin prophylaxis was kept for a median time of 28 days (first and third quartile: 15 and 30). However, median time of prophylaxis differed depending on the reason for prophylaxis: 30 days in TKR, THR, and HF surgery; 21 days in cast immobilization of the leg, other lower limb surgery, and spine surgery; and 15 days in knee arthroscopy.
The median observation period was 30 days (first and third quartile: 20 and 35). A total of 6456 (92%) of patients with well-documented reason for prophylaxis completed the last visit and therefore were assessed for VTE and adverse events.
Incidence of Venous Thromboembolism
VTE was clinically suspected and objectively confirmed in 59 out of 6456 assessable patients (0.91%; 95% CI: 0.70% to 1.18%: 7 proximal DVTs, 50 distal 
Adverse Events
Total adverse events rates depending on orthopedic procedure are shown in Table 3 . Overall, 306 of 6456 assessable patients (4.74%; 95% CI: 4.23% to 5.29%) experienced a bleeding event. Most events were wound bleedings (249 cases, 3.86%). Eleven bleeding events (0.17%; 95% CI: 0.09% to 0.30%) were major, requiring bemiparin discontinuation: 5 wound bleedings, 5 gastrointestinal bleedings, and 1 hematuria. There were no cases of fatal bleeding, bleeding in critical organs, or bleeding leading to reoperation.
A total of 24 of 6456 assessable patients (0.37%; 95% CI: 0.24% to 0.55%), 15 females and 9 males, died during the study (Table 3 ). These patients had a mean age of 85 years (range 66-98). None of the deaths were related to bleeding or any other adverse drug reaction. There were 3 deaths (0.05%; 95% a. There were 2 deaths in hip fracture surgery and 1 death in other lower limb surgery (calf fracture) in which fatal pulmonary embolism was suspected, but no confirmatory autopsy was performed.
CI: 0.01% to 0.14%) in which fatal PE was suspected (2 deaths in HF surgery and 1 death in calf fracture surgery). However, a confirmatory autopsy was not performed. The 3 suspected fatal PEs occurred between day 15 and day 20 after surgery. The causes of the remaining 21 deaths were heart failure/lung edema (5 patients), infection-sepsis (4 patients), myocardial infarction (2 patients), cancer (3 patients), respiratory failure (2 patients), and other (5 patients). Thrombocytopenia was found in 33 of 6456 assessable patients (0.51%; 95% CI: 0.35% to 0.72%). In these patients, platelet count ranged from 75 000 to 148 000/mm 3 . None of the cases required treatment discontinuation. There were no other clinically relevant laboratory abnormalities. Most local reactions at the injection site were mild ecchymoses. Twenty-seven patients (0.42%; 95% CI: 0.30% to 0.56%) developed injection site urticaria. Bemiparin was discontinued in 7 of these cases, none of which was severe. There were 6 cases (0.09%; 95% CI: 0.03% to 0.20%) of injection site hematoma, all of them <5 cm in diameter. There were no cases of hematoma at the injection site >5 cm in diameter or requiring treatment discontinuation. No rare or unexpected adverse drug reactions to bemiparin occurred during the study.
Major bleeding rates were very low and similar in patients receiving 2500 IU versus 3500 IU (0.26% vs 0.15%; Diff, 0.11%; 95% CI: -0.42% to 0.64%). Minor bleeding rates were lower in patients receiving bemiparin 2500 IU versus 3500 IU (1.05% vs 4.25%; Diff, -3.20%; 95% CI: -4.26% to -2.14%).
Overall, 3298 patients (41.4%) received concomitant NSAID (metamizol, diclofenac, etc) . Bleeding events were similar in patients who received concomitant NSAIDs and those who did not (4.09% vs 4.03% no NSAID; Diff, 0.06%; 95% CI: -0.82% to 0.94%). The percentage of patients receiving concomitant NSAIDs was similar among patients with bleeding events and those without bleeding events (41.80% vs 41.42%; Diff, 0.38%; 95% CI: -5.12% to 5.86%).
Elderly and Obesity
Overall, 1904 patients were 65 years or older, and 1881 patients were obese. Ninety-seven percent of elderly and obese patients received the bemiparin 3500 IU dose. Most elderly patients underwent TKR, THR, or HF surgery. Compared with younger patients, elderly patients more often had documented symptomatic VTE (1.62% vs 0.58%; Diff, 1.04%; 95% CI: 0.32% to 1.76%). Major bleeding rates were similar among elderly and younger patients (0.15% vs 0.22%; Diff, -0.07%; 95% CI: -0.29% to 0.15%).
Compared with nonobese patients, obese patients had a similar incidence of documented symptomatic VTE (1.38% vs 1.09%; Diff, 0.29%; 95% CI: -0.33% to 0.91%) and major bleeding (0.21% vs 0.15%; Diff, 0.06%; 95% CI: -0.18% to 0.30%).
Discussion
Bemiparin prophylaxis for 3 to 4 weeks was associated with a low incidence of VTE, bleeding, and other adverse events in "real-life" clinical practice. In agreement with the literature, the higher VTE rates were found in THR, TKR, and HF surgery. 1,2 VTE events were mainly distal DVTs.
Orthopedic patients undergoing THR, TKR, or HF surgery are usually at high VTE risk for several weeks after surgery. 1, 2 In our study, most cases of documented symptomatic VTE occurred during outpatient prophylaxis, and the 3 cases of suspected fatal PE occurred more than 2 weeks after the initial surgery. The published rate of symptomatic VTE during postdischarge thromboprophylaxis with LMWH for 3 weeks is 0.8%. 6 Current ACCP Consensus Statement recommends extended posthospital discharge prophylaxis for up to 28 to 35 days for patients undergoing THR or HF surgery. 1 Most patients in our study underwent cast immobilization of the leg. In this subpopulation, we found a low rate (0.45%) of symptomatic VTE up to 30 days. In patients with leg injury requiring cast immobilization of the leg, the rate of documented symptomatic VTE with placebo ranges from 3.2% to 4.5% up to 44 and 90 days, respectively. 7,8 LMWH significantly reduced DVT incidence compared with placebo in these patients 7, [9] [10] [11] at no cost to safety. Thus, thromboprophylaxis in patients with cast immobilization of the leg appears to be justified. 12 VTE appears to be dependant on the localization of the plaster cast and may be higher in those used for whole leg/knee/ankle cast. Unfortunately, data on plaster cast localization in our study are not available.
The need for and duration of thromboprophylaxis after knee arthroscopy is a matter of debate. 1, 2 The risk of documented symptomatic DVT after knee arthroscopy reported in the United States is approximately 0.6%, and American guidelines suggest that clinicians not use routine thromboprophylaxis in these patients other than early mobilization. 1 Without prophylaxis, symptomatic VTE rates up to 3.7% have been reported in day-care arthroscopy in Europe. 13 In our study, we found a very low incidence of documented symptomatic DVT (0.14%) in the subgroup of knee arthroscopy. Thromboprophylaxis after knee arthroscopy probably should be considered when there are concomitant risk factors of VTE, such as previous history of VTE or age > 40 years, prolonged operating or tourniquet time, or when a rapid postoperative mobilization of the patient is not feasible. 12, 14 There are also few data on the use of thromboprophylaxis in spine surgery. 1, 2, 15 The incidence of symptomatic DVT and PE in these patients without prophylaxis is approximately 3.7% and 2.2%, respectively. 15 In our study, bemiparin totally prevented documented symptomatic VTE in the subgroup of patients undergoing spine surgery. Spine surgery with central cord lesions or lumbar fusion seems to have a considerably higher risk on VTE than discal hernia surgery. Unfortunately, data on the type of spine surgery performed were not collected in our study.
As regards safety, we found a low incidence of major and minor bleeding complications within expected for extended prophylaxis with LMWH in orthopedic patients. 16 Most bleeding events were related to the surgery or injury site. Mortality rates were low. Patients undergoing HF surgery showed the highest mortality rates among patients included, in agreement with reports in the literature. 1, 2, 17 From a clinical standpoint, vascular events (heart failure, myocardial infarction, and/or suspected fatal PE) were the cause of death in 11 of 24 patients (46%) who died during our study. However, this study was conducted according to standard clinical practice, and no autopsy was performed among patients who died. Although prophylaxis results in a reduction in overall mortality and fatal PE, vascular events continue to be a common cause of mortality among orthopedic patients, contributing toward approximately 50% of all deaths. 18 In our study, concomitant administration of NSAIDs in orthopedic patients receiving bemiparin prophylaxis did not significantly increase major and minor bleeding rates. However, the potential for interaction exists and caution should be exercised in prescribing NSAIDs for patients being treated with LMWH. Elderly patients receiving bemiparin had similar rates of major bleeding to younger patients, and had higher rates of documented symptomatic VTE. Most elderly patients underwent procedures with a high VTE risk, such as HF surgery, THR, or TKR. In elderly patients undergoing major orthopedic surgery, adjuvant measures, such as prompt mobilization and the use of pneumatic compression devices and/or elastic stockings, may provide additional efficacy. 1 Obese patients had similar incidences of VTE and major bleeding to nonobese patients. These results suggest that during bemiparin thromboprophylaxis, VTE rates are not increased in obese patients and major bleeding rates are not increased in elderly patients. Similar results have been shown for LMWH in another clinical setting. 19 Finally, no rare or unexpected adverse drug reactions to bemiparin occurred during the study.
To the best of our knowledge, there are few direct randomized, double-blind comparisons between distinct LMWHs in orthopedic surgery. 5, 20, 21 In one of these studies, bemiparin showed a trend toward a lower incidence of symptomatic VTE and wound hematoma than enoxaparin in TKR, and a statistically significant reduction in risk of reactions at injection site in favor of bemiparin was observed. 5 In the economic analysis of this clinical trial, when overall clinical outcomes and costs were considered, bemiparin was dominant over enoxaparin, providing better overall clinical outcomes and cost savings. 22 In a prospective, comparative, nonrandomized study in THR, referenced in the review by Planes, 3 bemiparin was safer than enoxaparin or dalteparin with regard to mean blood loss through drainage (415 ml vs 599 ml, respectively; P = .046) and surgical wound complications (8% vs 31%, respectively; P = .003) in standard clinical practice. However, this latest observation requires confirmation in further randomized, doubleblind comparisons.
This study has several limitations. A large proportion of cast immobilization of the leg was included and represented a majority of the studied patients. On the contrary, a lower number of patients included in the study underwent HF surgery, THR, or TKR surgery. These procedures are associated with a higher VTE risk than cast immobilization of the leg. No comparison with other thromboprophylactic interventions was made. In addition, VTE screening tests are not usually performed in asymptomatic patients in standard clinical practice, thus potentially leading to an underestimation of VTE. However, observational studies in normal clinical practice add information that is not available in randomized controlled trials 23 where exclusion criteria, limited sample size, and use in specific clinical situations lead to significant loss of useful pragmatic data. Therefore, we were able to assess the real-life effect of bemiparin in a very large audit of orthopedic patients.
In conclusion, bemiparin prophylaxis given for 3 to 4 weeks in patients with cast immobilization of the leg and other orthopedic procedures was associated with low rates of VTE, bleeding, and other adverse events in normal clinical practice.
